Our community narratives are driven by numbers and valuation.
Value any stock for free in seconds
Get alerts and valuation updates
Participate in discussions
WA
Consensus Narrative from 18 Analysts
New Vaccines And HIV Advancements Will Shape Future Success
Key Takeaways Strong growth in Specialty Medicines and new product launches expected to drive revenue, particularly in HIV, Respiratory, and Oncology. Expanding portfolio with new vaccines and HIV advancements anticipated to impact earnings and market share positively.
View narrativeUK£18.17
FV
25.2% undervalued intrinsic discount3.98%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
19users have followed this narrative
17 days ago author updated this narrative